Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949139 | 0.88 | CYP1A2 (0.57) | HSD17B10USP2MAPTKDM4EALDH1A1 | |
| SCHEMBL670443 | 0.87 | CYP1A2 (0.57) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25337733 | 0.87 | USP2 (0.73) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL222268 | 0.86 | CYP1A2 (0.67) | HSD17B10USP2NPC1RAB9AMAPT | |
| SCHEMBL20602048 | 0.86 | MAPT (0.53) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4747905 | 0.86 | CYP1A2 (0.53) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1808476 | 0.85 | TSHR (0.63) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5981995 | 0.85 | HSD17B10 (0.75) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1345863 | 0.84 | MAPT (0.51) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8888393 | 0.84 | MAPT (0.51) | HSD17B10USP2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-113637017-B | Compound containing dihydropterin structure, its preparation method and application | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-20240067648-A1 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067648-A1 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2280982-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| WO-2009112524-A1 | PYRIDOPYRIMIDINES AS PLK1 ( POLO-LIKE KINASE) INHIBITORS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | HSD17B10 2996/4885USP2 1731/4885NPC1 2323/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | HSD17B10 770/4885USP2 4064/4885NPC1 1178/4885 |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | HSD17B10 844/4885USP2 4682/4885NPC1 136/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | HSD17B10 4617/4885USP2 1735/4885NPC1 4073/4885 |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | HSD17B10 1406/4885USP2 3686/4885NPC1 2145/4885 |
| US-20240067648-A1 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, CASP1 | HSD17B10 3026/4885USP2 1271/4885NPC1 272/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | HSD17B10 770/4885USP2 4064/4885NPC1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.